Study details
Enrolling now
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT IDNCT04701645ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 3.7 years
Ages
18+
Sex
Female only
Locations
2 sites in MA
What this study is about
This trial is testing a new way to measure how well cancer responds to treatment using an implantable microdevice. The goal of this pilot trial is to determine if the device can accurately track local tumor response in women with ovarian, fallopian tube, or primary peritoneal cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Microdevice
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Number of participants with adverse events as defined in the CTCAE v5.0
Body systems
Oncology